Bharat Book Bureau - Global Diabetes Market Trends & Future Forecast

“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering:

• Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
• Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
• Region wise Diabetes Health Expenditure and Mortality
• Top 10 Countries Diabetes Population and Future Forecast
• Top 5 Countries Diabetes Drug Market and Future Forecast
• Top 7 Countries Insulin Market and Future Forecast
• Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
• Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
• Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
• Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights

• USA controls more than 50% of the total Diabetes Drug market share in 2009
• Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
• China will have the second highest Insulin market share by 2012 replacing Germany
• DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
• GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
• Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
• Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
• Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
• Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
• China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
• Japan Insulin market is expected to be more than US$ 1 Billion by 2010

Key Drugs Analyzed

Diabetes Drug: Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix
Insulin: Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus
DPP-IV Inhibitors: Januvia, Onglyza, Alogliptin, Galvus,
GLP-1 Agonists: Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.

To know more and to buy a copy of the report “Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” (http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html) feel free to visit http://www.bharatbook.com or contact us at +91 22 27578668.

About the Author:
Bharat Book Bureau, the leading market research information aggregator provides reports, company profiles, newsletters, country info. and online databases for the past twenty two years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India.